Macular Edema – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
This report provides top-line data relating to the clinical trials on macular edema. The report includes an overview of trials count and their average enrollment in top countries conducted globally. It also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. Moreover, the report provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
The macular edema clinical trial report consists of 604 trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0. Out of 436 completed trials, more than 200 trials have achieved end points. The number of macular edema clinical trials conducted globally has decreased by more than 60% for the period 2016-2020. More than 60% of trials have been sponsored by institutions and about 30% were sponsored by companies.
What are the top regions and countries in the macular edema clinical trials market?
In total there were 604 clinical trials conducted on macular edema, as of December 2021. Out of these, more than 30% of the clinical trials were conducted in Asia-Pacific. In the region, Japan has the highest number of macular edema clinical trials, accounting for 35% of the total trials. North America and Europe covered the same percentage of clinical trials followed by the Middle East and Africa. Among the European countries, Germany has the highest number of macular edema clinical trials covering more than 20%. Iran has the highest number of macular edema clinical trials in the Middle East region accounting for over 35%. The least percentage of trials conducted were in South and Central America. Brazil covers more than 60% of the macular edema clinical trials there.
On a country basis, the US had the highest number of macular edema clinical trials, followed by Japan and China. France has the highest average patient enrollment in macular edema clinical trials. China and the US have the greatest number of clinical trials in progress. Other top countries include Germany, the UK, Italy, Spain, India, and South Korea.
Macular edema clinical trials market in G7 countries
Among the G7 countries (the US, the UK, Germany, France, Italy, Canada, and Japan), there were 439 clinical trials conducted as of 2021. Of these, the US had the highest number of clinical trials. The UK had the highest proportion of macular edema to ophthalmology clinical trials.
Macular edema clinical trials market in E7 countries
Among the E7 countries (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia), there were 151 clinical trials conducted as of December 2021. Of these, China had the highest number of clinical trials. Indonesia had the highest proportion of macular edema to ophthalmology clinical trials.
Macular edema clinical trials market, by region
For more regional insights, download a free report sample
What is the phase-wise outlook of the macular edema clinical trials market?
There were 266 clinical trials in Phase II, of which 24 clinical trials were in progress for the time period of 1995-2021. This was followed by the greatest number of clinical trials in Phase IV. This phase also had the greatest number of trials in progress accounting for more than 35% of the clinical trials in progress.
Which are the key sponsors in the macular edema clinical trials market?
The key sponsors in the macular edema clinical trials sector are Novartis AG, AbbVie Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Regeneron Pharmaceuticals Inc, Clearside BioMedical Inc, IQVIA Holdings Inc, Bausch Health Companies Inc, Pfizer Inc, and 3SBio Inc. Out of them Novartis AG has conducted the highest number of macular edema clinical trials.
Macular edema clinical trials sector, by key sponsors
To know more about key players, download a free report sample
Market report scope
Key regions | Asia-Pacific, North America, Europe, Middle East and Africa, and South and Central America |
Key countries | The US, Japan, China, France, Germany, the UK, Italy, Spain, India, and South Korea |
Key sponsors | Novartis AG, AbbVie Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Regeneron Pharmaceuticals Inc, Clearside BioMedical Inc, IQVIA Holdings Inc, Bausch Health Companies Inc, Pfizer Inc, and 3SBio Inc. |
The report provides an in-depth analysis of:
- Top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end point status.
- Top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- All the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- Enrollment trends for the past five years.
- Latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
AbbVie Inc
F. Hoffmann-La Roche Ltd
Bayer AG
Regeneron Pharmaceuticals Inc
Clearside BioMedical Inc
IQVIA Holdings Inc
Bausch Health Companies Inc
Pfizer Inc
3SBio Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key regions in the macular edema clinical trials market?
The key regions in the macular edema clinical trials market are Asia-Pacific, North America, Europe, Middle East and Africa, and South and Central America.
-
What are the key countries in the macular edema clinical trials market?
The key countries in the macular edema clinical trials market are the US, Japan, China, France, Germany, the UK, Italy, Spain, India, and South Korea.
-
Which are the key companies in the macular edema clinical trials market?
The key companies in the macular edema clinical trials market are Novartis AG, AbbVie Inc, F. Hoffmann-La Roche Ltd, Bayer AG, Regeneron Pharmaceuticals Inc, Clearside BioMedical Inc, IQVIA Holdings Inc, Bausch Health Companies Inc, Pfizer Inc, and 3SBio Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.